18 Dec Evolution Biotechnologies announces the appointment of Edward C. Cappabianca as Chief Business Officer
Bedford, UK, December 15th 2018
Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control in human disease, today announces the appointment of Mr. Edward C. Cappabianca as Chief Business Officer. Mr. Cappabianca has a strong background in investment banking, previously working with Alex. Brown & Sons, William Blair International, and Rodman & Renshaw, LLC. He also has operational management experience in the Biotech & Life Sciences sector having served as CEO of AmpliPhi Biosciences in the US and Founding CEO of EnXray in the UK.
Mr. Cappabianca said “I am very pleased to join Evolution as a part of the team to help grow and develop its products into world-leading treatments for human health applications. The approach being taken is novel and unique with the potential to deliver rapid results. Having worked closely with David in the past, initially as an investment banker, and subsequently as his colleague at AmpliPhi, I know that we will work well together on Evolution Biotechnologies’ development.
Dr. David Harper, CEO, said “I have worked very productively with Ed in the past and look forward to doing so again. I am genuinely delighted that he is joining the growing team at Evolution. His extensive network of contacts, together with his strong background in finance and biotechnology management, will help to prepare the company for our proposed listing. Having someone with Ed’s experience join the team is an important step in getting the company positioned for entry onto the public markets.”
About Evolution Biotechnologies
Evolution Biotechnologies (UK company 09473027 and US company 6050853) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, a market with high value and significant unmet need. Completion of a successful feasibility study on biological control of the house dust mite has led to national stage patent filings deriving from PCT filing WO2017025732 (A1). These are currently under examination in Europe, the USA, and other relevant jurisdictions. The company is also incubating additional projects based on biological control technologies.
About biological control
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of a proven technology into high value markets with unmet clinical need.
This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.